Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology

University of Milano

Director, Laboratory for the Study of Lipoproteins and Atherosclerosis

Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis

Bassini Hospital

Director, Center of Epidemiology and Preventive Pharmacology

University of Milano (SEFAP)

Immediate Past President, European Atherosclerosis Society (EAS)

Milan, Italy

Related Videos

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors? Video

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia? Video

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER? Video

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER? Video

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS? Video

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS, Video

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance? Video

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors? Video

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents? Video

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?